Analysis of the Correlation Between Serum Procalcitonin (PCT), C-Reactive Protein (CRP) Levels and the Occurrence/Severity of Bronchopulmonary Dysplasia in ELBW/VLBW Neonates

分析血清降钙素原(PCT)、C反应蛋白(CRP)水平与极低出生体重/超低出生体重新生儿支气管肺发育不良的发生/严重程度的相关性

阅读:1

Abstract

OBJECTIVE: This study aimed to analyze the correlation between serum levels of Procalcitonin (PCT) and C-reactive protein (CRP) and the occurrence and severity of Bronchopulmonary Dysplasia (BPD) in Extremely Low Birth Weight (ELBW) and Very Low Birth Weight (VLBW) neonates, and to identify associated risk factors. METHODS: A retrospective analysis was conducted on 213 ELBW/VLBW neonates admitted between January 2021 and January 2024. According to BPD diagnosis, they were categorized into a control group (n=62, without BPD) and an observation group (n=151, with BPD). The observation group was further stratified by severity into mild (n=71), moderate (n=46), and severe (n=34) BPD. Serum PCT and CRP levels were compared across groups. The correlation between these biomarkers and BPD severity was analyzed, and risk factors for BPD were investigated. RESULTS: PCT and CRP levels were significantly higher in the observation group than in the control group (P<0.05). A significant increasing trend in both PCT and CRP levels was observed with worsening BPD severity (P<0.05). Spearman analysis confirmed positive correlations between BPD severity and PCT (r=0.354) and CRP (r=0.472) levels (P<0.05). Multivariate logistic regression identified intrauterine infection, gestational age <28 weeks, assisted ventilation >2 weeks, infectious pneumonia, and FiO(2) >40% as independent risk factors for BPD (P<0.05). CONCLUSION: In this retrospective study, elevated serum PCT and CRP levels were positively associated with the severity of BPD in ELBW/VLBW neonates. The identified risk factors, including intrauterine infection, gestational age <28 weeks, prolonged assisted ventilation, infectious pneumonia, and high FiO(2), are independently associated with BPD. These findings suggest that monitoring these biomarkers and risk factors may warrant intensified clinical attention.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。